|
⚲
|
| Keyboard |
| Advent Life Sciences LLP
✚
|
|
|---|---|
| CRD # | 173031 |
| SEC # | 802-92178 |
| CIK # | 0001601364 |
| AUM | |
| Employees | |
| Fees | |
| Minimum | |
| Phone | 4402079322100 |
| Address | 27 Fitzroy Square London, United Kingdom |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Advent Life Sciences Growth Fund LP | 2025-03-20 | 170.8 M | |
| VC | Biomotiv LLC | [2022-03-29] | 145.7 M | 27.9 M |
| Offered $200,000,000 · Filed 2018-08-01 (D/A) · Exemption 506(b) · Remaining $54,273,210 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Advent-Harrington Impact Fund LP | [2021-03-12] | 41.6 M | 52.2 M |
| Filed 2020-11-06 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Commission $208,125 · Revenue Decline to Disclose | ||||
| VC | Advent Life Sciences II Co-Invest LP | 2020-03-04 | 18.6 M | |
| VC | Advent Life Sciences Fund III LP | [2019-03-22] | 24.8 M | 154.1 M |
| Filed 2019-12-06 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Advent Life Sciences Fund II LP | [2015-04-09] | 226.3 M | 159.2 M |
| Offered $226,271,136 · Filed 2014-11-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Advent Life Sciences Fund I LP | 2015-04-09 | 246.7 M | |
| AUM Breakdown | Accounts | AUM ($) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Discretionary | ||
| Discretionary | 0 | 0.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 0 | 0.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 0.0 | |
| Total | 0 | 0.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Shahzad Malik | Executive Officer | 35 | 2 | |
| Dale Pfost | Executive Officer | 13 | 2 | |
| Rajesh Parekh | Executive Officer | 11 | 2 | |
| Kaasim Mahmood | Executive Officer | 4 | 2 | |
| Advent Life Sciences Llp | Executive Officer | 4 | 2 | |
| Als III GP Llp | Executive Officer | 2 | 1 | |
| Kaaism Mahmood | Executive Officer | 1 | 1 | |
| Advent LS II LP | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001601364] | |
| 4 | [0001601364] | |
| SC 13D | [0001601364] | |
| SC 13G | [0001601364] |
| Firm Profile (Form ADV) | |
|---|---|
| LEI | 21380051AVIC1PCSR289 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Advent Life Sciences LLP | |
| Axonics Inc | |
| Advent Life Sciences Fund II LP | |
| Aravive Inc | |
| Advent Life Sciences Fund I LP |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Axonics Inc AXNX
Common Stock
|
2018-11-02 | Conversion | 1,231,178 | ||
|
Axonics Inc AXNX
Common Stock
|
2018-11-02 | Conversion | 404,937 | ||
|
Axonics Inc AXNX
Common Stock
|
2018-11-02 | Conversion | 43,822 | ||
|
Axonics Inc AXNX
Common Stock
|
2018-11-02 | Conversion | 14,412 | ||
|
Axonics Inc AXNX
Series B-2 Preferred Stock · derivative
|
2018-11-02 | Conversion | 1,025,981 | $0.00 | |
|
Axonics Inc AXNX
Series C Preferred Stock · derivative
|
2018-11-02 | Conversion | 337,447 | $0.00 | |
|
Axonics Inc AXNX
Series C Preferred Stock · derivative
|
2018-11-02 | Conversion | 12,010 | $0.00 | |
|
Axonics Inc AXNX
Series B-2 Preferred Stock · derivative
|
2018-11-02 | Conversion | 36,518 | $0.00 | |
|
Aravive Inc VSAR
Common Stock
|
2015-01-22 | Buy | 55,000 | $17.25 | 948,750 |
|
Aravive Inc VSAR
Common Stock
|
2014-03-26 | Conversion | 1,258,086 | ||
|
Aravive Inc VSAR
Common Stock
|
2014-03-26 | Conversion | 176,813 | ||
|
Aravive Inc VSAR
Common Stock
|
2014-03-26 | Conversion | 78,228 | ||
|
Aravive Inc VSAR
Common Stock
|
2014-03-26 | Conversion | 154,178 | ||
|
Aravive Inc VSAR
Common Stock
|
2014-03-26 | Conversion | 489,253 | ||
|
Aravive Inc VSAR
Warrants to Purchase Series B Preferred Stock · derivative
|
2014-03-26 | Option exercise | 506,376 | $0.00 | |
|
Aravive Inc VSAR
Series E Convertible Preferred Stock · derivative
|
2014-03-26 | Conversion | 1,773,049 | $0.00 | |
|
Aravive Inc VSAR
Series B Convertible Preferred Stock · derivative
|
2014-03-26 | Option exercise | 506,376 | $0.00 | |
|
Aravive Inc VSAR
Series B Convertible Preferred Stock · derivative
|
2014-03-26 | Conversion | 14,468,020 | $0.00 | |
|
Aravive Inc VSAR
Series C Convertible Preferred Stock · derivative
|
2014-03-26 | Conversion | 5,626,413 | $0.00 | |
|
Aravive Inc VSAR
Series D-1 Convertible Preferred Stock · derivative
|
2014-03-26 | Conversion | 2,033,350 | $0.00 | |
| showing 20 of 22 most recent transactions | |||||